While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Jake Shane exclusively told Us Weekly why he wanted his followers to think he was on Ozempic and what his hopes are for the ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

FDA could allow the drug into the market, as soon as next year, once Loyalhits certain safety and manufacturing milestones.

Nothing kills a laugh faster than seeing actors sweat The post ‘Operation Mincemeat’ Broadway Review: This British Import ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Only time will tell if the recently enacted health-care reform laws can rein in the uncontrollable costs that have created ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...